Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) produces 15-22.5 percent reductions depending on dose
[END CALLOUT BOX] GLP2 Pharmacokinetics & Metabolism Absorption & Distribution Following subcutaneous administration, GLP2 exhibits favorable pharmacokinetic properties enabling once-weekly dosing: Mean absolute bioavailability of approximately 80% after subcutaneous injection Time to maximum plasma concentration (Tmax) ranges from 8 to 72 hours Steady-state plasma concentrations achieved after 4 weeks of once-weekly dosing Mean steady-state volume of distribution approximately 10.3 L, indicating limited tissue distribution The high plasma protein binding to albumin (99%) results from the C20 fatty diacid modification, which provides prolonged systemic exposure and enables sustained therapeutic effects between weekly doses
The glucagon receptor component is hypothesised to enhance energy expenditure and fat breakdown, which researchers believe may contribute to greater weight loss compared with dual or single agonists though this remains under investigation and has not been definitively established
Y.WilleE.NaseriN.PetriS.DamianoM.et al (2011)
Training volume does not need to be extreme during a deficit
US$ 25.28
US$ 29.76
US$ 29.22
US$ 24.16
